OKYO · OKYO Pharma Limited
United States · RS rating 37 · As of 2026-11-03
| Price | 1.45 USD |
|---|---|
| 1-day change | -0.7% |
| RS rating (overall / 1M / 3M / 12M) | 37 / 53 / 50 / 23 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 23 / 9 / 20 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +53.4% |
| Market cap (USD) | $83.4M |